At a glance
ClinicalIndex Comparison RecordN/ACompleted· 13 enrolled
Drug / intervention
Ranibizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Genetic Analysis of Patients With Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab But Resistant to Aflibercept
In Brief
An observational study evaluating Ranibizumab and Aflibercept for Age-Related Macular Degeneration. Completed, enrolled 13 participants across 1 site.
Detailed Summary
A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartDec 2014
Primary CompletionJul 2015
TodayJul 2026
First PostedNov 17, 2014
Enrollment StartDec 22, 2014
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.6 years ago
Interventions
Ranibizumabdrug
Intravitreal injection of Ranibizumab
Afliberceptdrug
Intravitreal injection of Aflibercept